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ATP-binding cassette (ABC) transporters have been associated with drug resistance in various diseases.
TheMRPA gene, a transporter of ABCC subfamily, is involved in the resistance by sequestering metal-thiol
conjugates in intracellular vesicles of Leishmania parasite. In this study, we performed the molecular char-
acterization of the MRPA transporter, analysis of P-glycoprotein (Pgp) and aquaglyceroporin-1 (AQP1)
expression, and determination of antimony level in antimony-susceptible and -resistant lines of L. (V.)
guyanensis, L. (L.) amazonensis, L. (V.) braziliensis and L. (L.) infantum. PFGE analysis revealed an association
of chromosomal ampliﬁcation ofMRPA genewith the drug resistance phenotype in all SbIII-resistant Leish-
mania lines analyzed. Levels of mRNA from MRPA gene determined by real-time quantitative RT-PCR
showed an increased expression of two fold in SbIII-resistant lines of Leishmania guyanensis, Leishmania
amazonensis and Leishmania braziliensis. Western blot analysis revealed that Pgp is increased in the
SbIII-resistant L. guyanensis and L. amazonensis lines. The intracellular level of antimony quantiﬁed by
graphite furnace atomic absorption spectrometry showed a reduction in the accumulation of this element
in SbIII-resistant L. guyanensis, L. amazonensis and L. braziliensis lines when compared to their susceptible
counterparts. Interestingly, a down-regulation of AQP1 protein was observed in the SbIII-resistant L.
guyanensis and L. amazonensis lines, contributing for decreasing of SbIII entry in these lines. In addition,
efﬂux experiments revealed that the rates of SbIII efﬂux are higher in the SbIII-resistant lines of L. guyan-
ensis and L. braziliensis, that may explain also the low SbIII concentration within of these parasites. The
BSO, an inhibitor of c-glutamylcysteine synthetase enzyme, reversed the SbIII-resistance phenotype of
L. braziliensis and caused an increasing in the Sb intracellular level in the LbSbR line. Our data indicate that
the mechanisms of antimony-resistance are different among species of Leishmania analyzed in this study.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction neglected tropical disease comprises clinical manifestations thatLeishmaniasis is a complex of diseases caused by different spe-
cies of protozoan parasites belonging to the genus Leishmania. Thisrange from self-healing cutaneous (CL) and mucocutaneous
(MCL) skin lesions to a visceral (VL) form, which is lethal if
untreated (Ashutosh et al., 2007). In the NewWorld, L. (Leishmania)
infantum (syn. L. (L.) chagasi) (Kuhls et al., 2007) is the causative
agent of VL, whereas L. (L.) amazonensis and L. (Viannia) guyanensis
cause CL, and L. (V.) braziliensis causes CL and MCL (Marzochi and
Marzochi, 1994; Murray et al., 2005; Shaw, 2006). The disease is
endemic in 98 countries, especially in northern Africa, Asia, the
Mediterranean and Latin America, with more than 350 million
people at risk (Ashford et al., 1992; Alvar et al., 2012). There are
an estimated 12 million people infected worldwide (World Health
Organization, 2012). The estimated incidence of leishmaniasis is
approximately 0.2–0.4 million VL cases and 0.7–1.2 million CL
cases per year. More than 90% of global VL cases occur in six
countries: India, Bangladesh, Sudan, South Sudan, Ethiopia and
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Ethiopia, North Sudan, Costa Rica and Peru account for 70–75% of
global estimated CL incidence (Alvar et al., 2012).
The control of leishmaniasis relies mainly on chemotherapy.
The ﬁrst line choice of treatment against all forms of the disease
is based on the administration of pentavalent antimony-containing
compounds, such as sodium stibogluconate (SSG) (Pentostam)
and N-methyl-glucamine (Glucantime). The mechanisms of
action of antimony are not fully elucidated. It is known that SbV
acts on the amastigote form, inhibiting enzyme activity and the
oxidative pathway of fatty acids (Herwaldt, 1999). It is generally
agreed that trivalent antimony (SbIII) is the active form of the drug
against Leishmania amastigote and promastigote forms (Frézard
et al., 2009). Murray and Nathan (1988) demonstrated that
macrophage activation has a signiﬁcant effect on intracellular
parasite killing. It has been reported that SSG induces the
macrophage to produce leishmanicidal molecules like nitric oxide
(NO) and reactive oxygen species (ROS) by activation of signalling
pathways, leading to the elimination of intracellular Leishmania
donovani amastigotes (Basu et al., 2006). In an animal infection
model, the mode of action of SbV is dependent on a number of
factors including T cell subsets and cytokines (reviewed by Murray,
(2001)). Furthermore, SbV was found to be a potent inhibitor of
protein tyrosine phosphatases, leading to an increase in cytokine
responses (Pathak and Yi, 2001). Thus, these results suggest
that SSG may kill the parasites by both direct and indirect
mechanisms. Studies suggest that SbIII causes disturbances in the
thiol redox potential of the parasite by inducing the efﬂux of
intracellular thiols and by inhibiting trypanothione reductase,
leading the cell to death by oxidative stress (Wyllie et al., 2004;
Moreira et al., 2011). It has been shown that antimony kills the
parasite by a process involving DNA fragmentation and external-
ization of phosphatidylserine on the outer surface of membrane
(Sereno et al., 2001; Lee et al., 2002; Sudhandiran and Shaha,
2003).
Drug resistance is one of the major clinical problems for the
treatment of various diseases ranging from bacteria and parasite
infections to cancer. Treatment failure with pentavalent antimoni-
als has been reported recently in several countries. In India, over
60% of patients with VL do not respond to treatment with pentava-
lent antimony drugs, due to acquired resistance (Sundar et al.,
2000). The mechanisms by which species of Leishmania acquire
resistance to antimonials have been subject of intensive research
for several decades. It has been described that resistance is an
interplay between uptake, efﬂux and sequestration of active mole-
cules (reviewed by Croft et al., 2006). A down-regulation of aqua-
glyceroporin-1 (AQP1) is correlated with lower SbIII uptake,
decreasing the drug concentration within the cell (Marquis et al.,
2005). On the other hand, ampliﬁcation of DNA segments has been
observed in several Leishmania species selected for drug resistance
(Beverley, 1991; Ouellette and Borst, 1991).
ATP-binding cassette (ABC) transporters have been associated
with drug resistance in various diseases. These transporters com-
prise an ancient superfamily of evolutionarily conserved proteins
spanning from bacteria to humans (Dassa and Bouige, 2001). They
are integral membrane proteins involved in the energy-dependent
transport of a variety of molecules across biological membranes,
including amino acids, sugars, peptides, lipids, ions and chemo-
therapeutic drugs (Higgins, 1992). In mammals, these transporters
are associated with chemoresistance mainly through overexpres-
sion of the multidrug-resistance (MDR) proteins (Borst et al.,
2000). In Leishmania, the ﬁrst ABC protein identiﬁed was MRPA
(PgpA) (Ouellette et al., 1990) which is a member of the ABCC sub-
family able to confer resistance to antimonials by sequestering me-
tal-thiol conjugates into an intracellular vesicle (Légaré et al.,
2001).Different mechanisms of drug resistance have been identiﬁed in
Old Word Leishmania species (reviewed by Croft et al., 2006).
Although there is considerable evidence showing variability in
the response to antimony chemotherapy in NewWorld pathogenic
Leishmania species (Moreira et al., 1998; Romero et al., 2001), the
mechanisms of drug resistance in these species have not been
extensively analyzed. Therefore, understanding the biological
diversity and responses to chemotherapy of different New World
Leishmania species is necessary to ultimately overcome current
limitations in anti-parasitic drug treatment. Thus, in this study
we performed the molecular characterization of the MRPA trans-
porter and determination of antimony level in antimony-suscepti-
ble and -resistant lines, which were experimentally induced, in
four New World Leishmania species: Leishmania guyanensis, Leish-
mania amazonensis, Leishmania braziliensis and Leishmania infan-
tum. Promastigote forms were characterized for: chromosomal
location, analysis of ampliﬁcation and mRNA levels of the MRPA
gene; Pgp and APQ1 protein expression; measurement of intracel-
lular antimony level, efﬂux rates of SbIII and susceptibility of L. bra-
ziliensis lines to BSO, an inhibitor of c-glutamylcysteine synthetase
(GCS) enzyme.2. Materials and methods
2.1. Leishmania strains
In this study, we used promastigote forms of four different New
World Leishmania species: L. guyanensis, L. amazonensis, L. brazilien-
sis and L. infantum (Table 1). These lines were selected in vitro to
trivalent antimony (SbIII) by step-wise drug pressure and the resis-
tance index varied from 4 to 20-fold higher than of their wild-type
counterparts (Liarte and Murta, 2010). This previous study showed
that the SbIII-resistant lines of L. amazonensis, L. braziliensis and L.
infantum have cross-resistance to paromomycin. Parasites were
grown at 26 C in M199 medium (Liarte and Murta, 2010).
2.2. Pulsed ﬁeld gel electrophoresis (PFGE)
Chromosomal DNA from Leishmania lines (2.0  109 cells/mL)
was prepared in low-melting temperature agarose plugs as de-
scribed by Smith et al. (1988). The agarose blocks containing intact
Leishmania chromosomes were separated by PFGE in 1% agarose
gels in 0.5x TBE (45 mM Tris-HCl, 45 mM boric acid, 1 mM EDTA,
pH 8.3) using the Gene Navigator TM System (Amersham Pharma-
cia, Buckinghamshire, UK). The running buffer (0.5x TBE) was
maintained at 9 C throughout the electrophoresis. Saccharomyces
cerevisiae chromosomes were used as size markers (Bio-Rad Inc.,
Hercules, CA, USA). Electrophoresis conditions were standardized
to allow the separation of the greatest number of parasite chromo-
somes in a single gel, as follows: 90 s for 18 h, 200 s for 18 h, 400 s
for 22 h and 600 s for 7 h at 90 V. A range from 365 to 2200 kb was
used for wide separation of Leishmania chromosomes. After elec-
trophoresis, gels were stained with ethidium bromide (10 lg/mL)
and bands were then transferred onto nylon membrane (Sambrook
et al., 1989). The MRPA gene was identiﬁed by incubation of the
membrane with the 32P-labelled MRPA gene probe. For this probe,
was used a 452 bp MRPA fragment (LbrM23_V2.0280) ampliﬁed
with the primers: forward 5’-TCGTGATTATTCCGTGCGCGTT-3’ and
reverse 5’-ACGCTCCACGCTGTTCATGTTT-3’.
2.3. Southern blot
Genomic DNA was isolated from the antimony-susceptible and
-resistant Leishmania species according to the protocol described
by Sambrook et al. (1989). Approximately 10 lg total DNA of
Table 1
Leishmania species used in this study*.
Species Strains IC50 (lM) Resistance index
WTS SbR
L. (V.) guyanensis IUMB/BR/85/M9945 0.09 ± 0.04 1.64 ± 0.14 19
L. (L.) amazonensis IFLA/BR/67/PH8 0.28 ± 0.15 1.71 ± 0.11 6
L. (V.) braziliensis MHOM/BR/75/M2904 0.15 ± 0.15 3.04 ± 0.13 20
L. (L.) infantum MHOM/BR/74/PP75 0.33 ± 0.09 1.40 ± 0.04 4
IC50 is the concentration (lM) of SbIII that decreases the rate of cell growth by 50%.The values represent the means ± CI (conﬁdence interval) of three independent
experiments in triplicate.
* Reference: Liarte and Murta (2010).
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(Invitrogen, Carlsbad, CA, USA). The fragments were separated by
electrophoresis on a 1% agarose gel and transferred to nylon mem-
brane (Sambrook et al., 1989). The blots were hybridized with
[a-32P]dCTP labeled MRPA gene probe as described above.
Leishmania DNA polymerase gene (LbrM.16.1600) was used as quan-
titative control. A fragment of 483 bp from this gene, after ampliﬁ-
cation using primers: forward 5’-GAAGACAGAGAAGGATGCGA-3’
and reverse 5’-GAGAGCGGGCACCAATCAC-3’, was used as probe.
The band intensities were analyzed using the software CP ATLAS
2.0 (http://lazarsoftware.com/download.html).
2.4. Quantitative real-time RT-PCR
Reverse transcription reactions for ﬁrst strand complementary
DNA (cDNA) synthesis were carried out as described below. Each
reaction contained 2 lg total RNA, 0.5 lg oligo d(T), 1x ﬁrst strand
buffer, 10 mM DTT, 0.5 mM dNTP, 40 U RNasin and 200 U Super-
script II reverse transcriptase in a ﬁnal volume of 20 lL. All the re-
agents used were obtained from Invitrogen (Life Technologies,
Carlsbad, CA, USA). All reactions were allowed to proceed for 1 h
at 42 C before being stopped by incubation at 70 C for 20 min.
The obtained cDNA was then diluted 15x in water and 5 lL of
the reaction product was ampliﬁed by real-time PCR using speciﬁc
primers. Ampliﬁcation reaction was carried out using the 7000 Sys-
tem SDS Software (PE Applied Biosystems, Foster City, CA, USA).
The primers, MRPA forward: 5’-AAGTGGGCAGCGACTCAAA-3’ and
MRPA reverse: 5’-CCAGTTCAGCGTCTCCGTT-3’, were the same de-
scribed by Torres et al. (2010) and Adaui et al. (2011). The DNA
polymerase constitutive gene from L. braziliensis (LbrM.16.1600)
was used to normalize the amount of sample analyzed. A fragment
of 69 bp of the DNA polymerase gene was ampliﬁed with the prim-
ers forward: 5’-CGAGGGCAAGACATAC-3’ and reverse: 5’-GAGA-
GCGGGCACCAATCAC-3’. Both pair of primers MRPA and DNA
polymerase ampliﬁed fragments of 81 and 69 bp respectively, in
all four Leishmania species analyzed (data not shown). PCR was
carried out in a ﬁnal volume of 20 lL of reaction mixture contain-
ing 10 pmol of forward and reverse primers, 1x SYBR GREEN reac-
tion mix (Applied Biosystems, Life Technologies, Carlsbad, CA, USA)
and 5 lL of template DNA. The PCR conditions were as follows: an
initial denaturation step at 95 C for 10 min followed by 40 cycles
of denaturation at 95 C for 15 s and annealing/extension at 60 C
for 1 min. Standard curves were prepared for each run using
known quantities of TOPO PCR 2.1 plasmids (Invitrogen, Life Tech-
nologies, Carlsbad, CA, USA) containing the MRPA and DNA poly-
merase genes. Estimates of DNA levels were obtained using the
Sequence Detection System data analysis software. Values were
normalized to those obtained for DNA polymerase for each sample.
2.5. Western blot analysis
Total proteins and membrane protein fractions from different
Leishmania lines were extracted according to the protocolsdescribed by Gamarro et al. (1994) and Grogl et al. (1991), respec-
tively. Protein extracts were separated by electrophoresis on a 12%
SDS polyacrylamide gel and electrotransferred onto nitrocellulose
membranes (Bio-Rad, Hercules, CA, USA). The blots were blocked
by incubationwith 5% instant non-fat drymilk in PBS supplemented
with 0.05% Tween 20 (PBS-T) for 1 h. The blots were then washed
twice in PBS-T and incubated for 16 h at 4 C in the presence of anti-
bodies:monoclonal antibody C219 (1:100) (Abcam, Cambridge, UK)
or rabbit polyclonal antibody anti-AQP1 (1:5) (kindly provided by
Andrade et al. – in preparation). The blots were washed and incu-
batedwith anti-IgGmouseHRP-conjugate (1:2,000) (GEHealthcare)
or HRP-conjugated anti-rabbit IgG (1:5,000) (GE Healthcare) for 1 h
at room temperature. After, the blots were exposed to Amersham
ECL Plus detection agent according to the manufacturer’s instruc-
tions and exposed to an X-ray ﬁlm (Amersham, Buckinghamshire,
UK). The resultswere normalizedusing the anti-a-tubulinmonoclo-
nal antibody (Sigma, St. Louis, USA). The intensity of the bands was
analyzed using the software CP ATLAS 2.0.
2.6. Antimony transport assays
2.6.1. Uptake assay
Before performing the uptake and efﬂux assays, the SbIII-resis-
tant lines are maintained at least two passages in M199 medium in
the absence of SbIII, in order to eliminate the residual drug. The
antimony uptake assay was based on two protocols previously de-
scribed (Roberts and Rainey, 1993; Wang et al., 2003). Log phase
Leishmania promastigotes were washed twice in a HEPES/Glucose
(HG) buffer (20 mM HEPES, 0.15 M NaCl, 10 mM glucose, pH 7.2)
and resuspended in this buffer at a density of 1.0  108 cells/mL.
The volume of 1 mL of this parasite suspension was aliquoted into
tubes in quadruplicate: tubes containing only parasites (blank) and
tubes with parasites in the presence of 540 lM SbIII (potassium
antimonyl tartrate) (Sigma, Saint Louis, MO, USA). Cells were then
incubated at 26 C for 1 h under agitation. Subsequently, the cells
were centrifuged at 1816g for 5 min at 4 C and washed three
times with HG buffer. Pellets were then resuspended with 100 lL
HG buffer. One aliquot of 10 lL of each tube was used for normal-
ization (parasite quantiﬁcation) and the remaining volume (90 lL)
was submitted to digestion with nitric acid (65%). Antimony con-
centration was quantiﬁed by graphite furnace atomic absorption
spectrometry (Perkin Elmer AAnalyst 600). Each uptake assay
was performed three times and the signal from blanks was used
for background subtraction.
In addition, the antimony-susceptible and -resistant lines of the
species L. guyanensis and L. braziliensis were evaluated for the
kinetics of incorporation of Sb. The parasites were incubated with
540 lM SbIII and, at different time intervals (0, 0.5, 1, 2 and 3 h),
1 mL aliquots of the parasite suspension were taken and they were
submitted to the protocol described above. This assay was also per-
formed to identify the time points at which the WTS and SbR lines
exhibit the same intracellular concentration of Sb, to be explored in
the efﬂux protocol.
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Log phase antimony-susceptible and -resistant L. guyanensis
and L. braziliensis cells were washed twice with HG buffer and
resuspended in this buffer at a density of 1.0  108 cells/mL.
Aliquots of 1 mL containing only parasites (blank) were taken
and the remaining cells were incubated with 540 lM SbIII for each
1 mL (potassium antimonyl tartrate) (Sigma, Saint Louis, MO, USA)
at 26 C under agitation. The WTS lines of L. guyanensis and L.
braziliensis were incubated during 2 min and 30 min, respectively.
Both SbR lines of these species were incubated for 70 min. After
incubation, the cells were centrifuged at 890g for 5 min at 4 C
and washed two times with HG buffer. The pellets were then
resuspended with HG buffer at the original density and the
cells were incubated at 26 C under agitation. Aliquots of 1 mL
were taken from the parasite suspension at the times 0, 1 and
2 h. Subsequently, these aliquots and the blanks were centrifuged
at 890g for 5 min at 4 C and washed three times with HG buffer.
After the last centrifugation, the pellets were resuspended
with 100 lL HG buffer. One aliquot of 10 lL of each tube was used
for normalization (parasite quantiﬁcation) and the remaining
volume (90 lL) was submitted to digestion with nitric acid (65%).
Antimony concentration was quantiﬁed by graphite furnace
atomic absorption spectrometry (Perkin Elmer AAnalyst 600).
Each efﬂux assay was performed three times in triplicate
and the SbIII dosage from blanks was used for background
subtraction.
2.6.3. Test of susceptibility to BSO and SbIII uptake in L. braziliensis
lines pre-treated with this inhibitor
Approximately 2.0  106 cells/mL of L. braziliensis were grown
in M199 medium containing various concentrations (2.5–30 mg/
mL) of buthionine-sulphoximine (BSO) (Sigma) during 48 h at
26 C. BSO is an inhibitor of c-glutamylcysteine synthetase (c-
GCS), a rate-limiting enzyme in thiol biosynthesis (Grifﬁth and
Meister, 1979). The drug concentration that decreases cell growth
by 50% (IC50) was determined by counting the parasites in the
presence and absence of the BSO. After pre-treatment with BSO,
the uptake of Sb was investigated in both susceptible and resistant
L. braziliensis lines. These parasites were ﬁrst grown in M199
medium for 48 h in the presence BSO at their respective IC50. Sub-
sequently, the cells were washed twice with HG buffer, resus-
pended in this buffer at a density of 1.0  108 cells/mL and
submitted to the uptake assay.Fig. 1. Chromosomal location of the MRPA gene in the antimony-susceptible (WTS) and
species were separated by PFGE and stained with ethidium bromide. (B) Proﬁle of th
chromosomes from Saccharomyces cerevisiae were used as molecular weight markers. The2.7. Statistical analysis
Data were analyzed by Student’s t test performed using the soft-
ware GraphPad Prism 5.0. A p value of <0.05 was considered statis-
tically signiﬁcant.
3. Results
3.1. MRPA ampliﬁcation in SbR Leishmania parasites
The molecular karyotype of antimony-resistant and -suscepti-
ble Leishmania lines, obtained through PFGE is presented in
Fig. 1A. Overall, the pattern of the physical chromosomal map ob-
tained for Sb-resistant and -susceptible Leishmania parasites is
similar except for LgSbR, which, in comparison with its parental
WT strain, showed a supplementary band of approximately
1900 kb (Fig. 1A white arrow). The pattern of hybridization of
the chromosomes showed that the MRPA gene probe recognized
a chromosomal band of approximately 800 kb in all lines of Leish-
mania analyzed (Fig. 1B) which ﬁts with the size of chromosome 23
(795 kb). In a preliminary analysis, the intensity of this band was
increased in the SbIII-resistant line of L. amazonensis. An interest-
ing observation in the antimony-resistant line of L. braziliensis
(LbSbR) is that the MRPA gene probe recognized in this sample a
DNA smear and two other bands of approximately 200 kb and
1500 kb (Fig. 1B). This result indicates an extrachromosomal
ampliﬁcation ofMRPA gene in LbSbR. In agreement with this obser-
vation, another band of approximately 700 kb was observed in the
resistant sample of L. infantum (Fig. 1B).
Southern blot assays were carried out using samples of genomic
DNA from different Leishmania lines previously digested with the
endonuclease BamHI, which has one restriction site within MRPA
gene (LbrM23_V2.0280) in a conserved region. Hybridization of ny-
lon membranes containing BamHI-digested DNA against a MRPA-
speciﬁc probe revealed a major band of 11.0 kb and other faint
band of 5.0 kb in all samples analyzed (Fig. 2A). Considering the
11 kb band, after normalization using a DNA polymerase gene probe
(Fig. 2B), the densitometry revealed an increased intensity of
three- and ten-fold in antimony-resistant L. amazonensis and L. bra-
ziliensis lines, respectively, when compared to their susceptible
counterparts. This data conﬁrms MRPA gene ampliﬁcation in these
antimony-resistant Leishmania lines. No difference was observed in
the other Leishmania lines analyzed.-resistant (Sb-R) lines of Leishmania. (A) Chromosomal bands from the Leishmania
e chromosomal bands hybridized with a 32P-labelled MRPA-speciﬁc probe. Whole
white arrow shows an additional band of approximately 1900 kb in the LgSbR line.
Fig. 2. Southern blot analysis of the MRPA gene from antimony-susceptible (WTS) and -resistant (Sb-R) Leishmania lines. Total DNA were digested with the BamHI (A)
endonuclease, subject to electrophoresis on a 1% agarose gel. Southern blots were hybridized with a 32P-labelledMRPA-speciﬁc probe. As control, the membrane was exposed
to a Leishmania DNA polymerase gene probe (B).
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MRPA mRNA levels in the Leishmania lines were evaluated by
real-time RT-PCR. Measurements of total RNA were normalized
by comparison with those obtained for the housekeeping gene
DNA polymerase (LbrM.16.1600). Then, a standard curve was ob-
tained using serial dilutions (107–102 molecules) of plasmids con-
taining the DNA polymerase and MRPA genes cloned into pCR2.1
TOPO vector. We obtained a standard curve with good linearity
for both genes (r2 = 0.998 to DNA polymerase and r2 = 0.973 to
MRPA). Our data showed a slope of 3.78 and 3.60 for the DNA
polymerase andMRPA genes, respectively, indicating high efﬁciency
of PCR (results not shown). The speciﬁcity of PCR was analyzed by
plots of the temperature-dependent dissociation of the SYBR
GREEN dye from the MRPA and DNA polymerase PCR products.
The results revealed that ﬂuorescence was only emitted at one
temperature, suggesting that only one PCR product was generated
in each reaction (results not shown).
The amount of cDNA ampliﬁed in the samples of Leishmania
spp. was determined by linear regression analysis using the Ct val-
ues obtained from the standard curve generated with known
amounts of the plasmids of the MRPA gene, normalized with DNA
polymerase values. The results showed that mRNA level fromMRPA
gene is increased two-fold in the antimony-resistant L. guyanensis,
L. amazonensis and L. braziliensis lines compared with their respec-
tive susceptible pairs. No difference in the MRPA gene expression
between antimony-resistant and -susceptible lines of L. infantum
was observed (Fig. 3).
3.3. Expression level of Pgp
We also determined the levels of Pgp in the antimony-suscepti-
ble and -resistant Leishmania lines by Western blot analysis using aFig. 3. Levels of transcription of the MRPA gene in Leishmania spp. susceptible and resis
polymerase Leishmania gene) by real-time RT-PCR. Mean values of the transcript levels M
indicated. The mean values for LgWTS and LgSbR, LaWTS and LaSbR and LbWTS versus Lb
whilst the LiWTS versus LiSbR mean values show no difference.monoclonal antibody (C219). According to manufacturer’s instruc-
tions (Abcam), this antibody recognizes an internal, highly
conserved amino acid sequence: VQEALD and VQAALD, corre-
sponding to the C-terminal and N-terminal regions, respectively,
found in both MDR1 and MDR3 isoforms of P-glycoprotein of
mammals. The results revealed that the C219 antibody recognized
a polypeptide of 170 kDa in some Leishmania samples analyzed
(Fig. 4B). According to literature data, this polypeptide corresponds
to the expected size of Pgp (Cornwell et al., 1987). Interestingly,
this antibody detected Pgp only in antimony-resistant L. guyanensis
and L. amazonensis lines, but not in the susceptible ones. This result
indicates that Pgp is more expressed in these antimony-resistant
Leishmania lines, whereas the Pgp levels in the susceptible lines
were not high enough for detection. On the other hand, this anti-
body recognized Pgp in both antimony-susceptible and -resistant
L. infantum lines. Densitometry using a-tubulin levels for
normalization showed the same level of Pgp expression between
both L. infantum lines (Fig. 4C). Additionally, we observed that
the C219 antibody also detected another polypeptide of about
48 kDa in all antimony-susceptible and -resistant Leishmania lines
analyzed. However, the intensity of this polypeptide was very faint
for both L. braziliensis lines (Fig. 4B). The presence of this 48 kDa
polypeptide can be due to antibody recognition of a common
epitope of another protein of Leishmania or an original fragment
of Pgp. It is described in the literature that this same anti-Pgp
C219 antibody recognizes smaller polypeptides named as ‘‘Pgp-
like’’ components (Grogl et al., 1991; Murta et al., 2001; Anacleto
et al., 2003).
It is important to emphasize that the anti-Pgp antibody did not
detect the protein of 170 kDa in any of the two L. braziliensis lines.
This result may be due to the absence of overexpression of Pgp in
the LbSbR line or changes may have occurred in the amino acid
sequence of the epitope region of the protein, preventing itstant lines. Levels of MRPA mRNA as determined quantitatively (relative to the DNA
RPA/DNA polymerase ± standard deviations from three independent experiments are
SbR are signiﬁcantly different (⁄p < 0.002, ⁄⁄p < 0.003 and ⁄⁄⁄p < 0.001, respectively),
Fig. 4. Pgp expression levels in Leishmania species. (A) Electrophoretic proﬁle of proteins from antimony-susceptible (WTS) and -resistant (Sb-R) Leishmania lines. Proteins
were separated by SDS-PAGE on 12% gel and stained with Coomassie blue. (B) Western blot analysis using the monoclonal antibody C219. (C) The membrane was normalized
with the a-tubulin antibody.
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whether the protocol used for total protein extraction was
appropriate or not to investigate the Pgp expression that is a
transmembrane protein. Thus, a protocol described by Grogl
et al. (1991) was also used to obtain enriched fraction of
membrane proteins separate from soluble protein fraction. After
extraction, the membrane proteins fractions of all Leishmania lines
were submitted to western blot analysis using the C219 antibody.
However, the results obtained with this protocol (results not
shown) were similar from those previously obtained using total
protein (Fig. 4B).3.4. Intracellular accumulation of antimony
In order to compare the level of antimony uptake between
antimony-susceptible and -resistant Leishmania lines, the parasites
were incubated for 1 h in the presence of 540 lM antimony
and, after washing, the intracellular antimony level was quantiﬁed
by graphite furnace atomic absorption spectrometry. Fig. 5 shows
that the uptake of antimony in the resistant lines was signiﬁcantly
reduced in three out of four species analyzed. The data indicate that
the antimony levels were approximately seven-, ﬁve- and two-fold
lower in the antimony-resistant L. guyanensis (Fig. 5A), L.
amazonensis (Fig. 5B) and L. braziliensis (Fig. 5C) lines, when
compared to their susceptible pairs, respectively. However, the sus-
ceptible and resistant lines of L. infantum (Fig. 5D) showed no statis-
tically signiﬁcant difference in the antimony incorporation. The
graphics also show marked differences in the level of antimony
incorporation between the different species studied.
In addition, these results of antimony intracellular accumula-
tion demonstrate that there is an inverse correlation between the
intrinsic antimony susceptibility of the Leishmania wild-type lines
used in this study and their ability to accumulate antimony. For
example, the LgWTS line, which is relatively more Sb sensitive
when compared to LiWTS (IC50 0.09 lM versus IC50 0.33 lM,
respectively, a 3.7-fold difference), accumulated 14-fold less Sb.
The same remark can be made for other lines of Leishmania. The
LgWTS line accumulated 2.8-fold less Sb than the LaWTS line
(IC50 0.28 lM, a 3-fold difference) and the LbWTS line (IC50
0.15 lM) accumulated 5-fold less Sb than the LiWTS line (a 2.2-
fold difference in IC50).3.5. Susceptibility of L. braziliensis lines to BSO and the effect of this
inhibitor in the SbIII uptake
We also investigated the effect of BSO, an inhibitor of c-glutam-
ylcysteine synthetase (GCS) enzyme, in the intracellular accumula-
tion of antimony by LbWTS and LbSbR lines pre-treated with this
inhibitor. Interestingly, the BSO susceptibility assay showed that
the LbSbR line is more susceptible to BSO than its susceptible coun-
terpart LbWTS. The IC50 obtained for LbWTS and LbSbR lines were
15 mM and 2.5 mM, respectively. Then, these lines were pre-trea-
ted with BSO during 48 h, incubated with SbIII by 1 h and then sub-
mitted to antimony uptake measurement (uptake assay). Our
results revealed that LbSbR line accumulated more SbIII compared
to its susceptible pair (LbWTS) (Fig. 5E). On the other hand, with-
out BSO, the LbSbR line accumulates less SbIII (Fig. 5C). These re-
sults suggest that BSO probably decreases the intracellular
concentration of thiols, interfering directly on the SbIII-thiol com-
plex formation and leading to the SbIII accumulation. In addition,
we determined the SbIII IC50 for the LbWTS and LbSbR lines in
the absence and presence of BSO. The LbWTS and LbSbR lines were
pre-treated with 15 mM and 2.5 mM BSO, respectively, during
48 h. Subsequently, we incubated these parasites with different
SbIII concentrations for 48 h. The IC50 obtained for the LbWTS line
in the absence of BSO was 0.025 mg/mL and in the presence of BSO
was 0.00625 mg/mL (4-fold lower). On the other hand, for the
LbSbR line the IC50 was 2 mg/mL and after pre-treatment with
BSO it was 0.0625 mg/mL (32-fold lower), indicating that the BSO
reversed the SbIII resistance phenotype.3.6. Inﬂux and efﬂux of antimony
Initially, we performed inﬂux kinetics analysis for the lines of L.
guyanensis and L. braziliensis. Our results showed that both SbR
lines exhibited lower rate of inﬂux of SbIII than their respective
susceptible counterparts, the difference being much more pro-
nounced in the case of L. guyanensis species (Figs. 6A and B). In or-
der to compare the efﬂux of Sb between susceptible and resistant
lines, cells were ﬁrst loaded with about the same level of antimony.
Subsequently, the parasites were washed with HG buffer and ali-
quots were taken at the times 0, 1 and 2 h to analyze the efﬂux
of antimony by graphite furnace atomic absorption spectrometry.
Fig. 5. Antimony uptake in promastigote forms of antimony-susceptible (WTS) and -resistant (Sb-R) lines from four different species of Leishmania. Intracellular antimony
was quantiﬁed by graphite furnace atomic absorption spectrometry after incubation with 540 lM SbIII for 1 h. The values obtained from three independent experiments in
quadruplicate, the mean antimony concentration ± SEM and the value p are represented in the graphics for the species: L. (V.) guyanensis (A), L. (L.) amazonensis (B), L. (V.)
braziliensis (C) e L. (L.) infantum (D). The effect of BSO in the SbIII uptake by parasites pre-treated with this inhibitor was also investigated in both L. (V.) braziliensis lines (E).
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both antimony-resistant lines of L. guyanensis and L. braziliensis,
when compared their susceptible pairs (Fig. 6C and D, respec-
tively). This efﬂux data explains, at least in part, the lower SbIII
concentration found in both SbIII-resistant lines, as presented in
the Fig. 5A and C, respectively.
3.7. Decreased expression of AQP1 in SbR Leishmania
In order to investigate whether the lower level of intracellular
antimony in the SbIII-resistant lines was due to down-regulation
of AQP1 protein, we evaluated the expression level of this protein
in the four Leishmania species studied. Western blot analyses with
membrane proteins fractions were performed using a rabbit poly-
clonal antibody anti-AQP1. Our results showed that this antibody
recognized a polypeptide of approximately 35 kDa in all anti-mony-susceptible and -resistant lines of Leishmania analyzed
(Fig. 7). After normalization using an a-tubulin antibody, quantiﬁ-
cation of the band intensity demonstrated that AQP1 expression le-
vel is decreased 1.7 and 3-fold in SbIII-resistant lines of L.
amazonensis and L. guyanensis, respectively, when, compared to
their respective susceptible pairs (Fig. 7). These data are consistent
with the lowest SbIII accumulation presented by these two lines
among the species studied (Fig. 5). On the other hand, the expres-
sion level of AQP1 was similar between the SbIII-susceptible and
-resistant lines of L. braziliensis and L. infantum showing band inten-
sities ratio (WT/SbR) values of 0.9 and 0.8, respectively (Fig. 7).
4. Discussion
The phenomenon of resistance to antimonials in Leishmania is
complex, multifactorial and involves several pathways, which have
Fig. 6. Time course of SbIII uptake and efﬂux in promastigote forms from antimony-susceptible (WTS) and -resistant (Sb-R) Leishmania lines. The kinetics of uptake and efﬂux
of SbIII were determined by graphite furnace atomic absorption spectrometry in WTS and Sb-R lines of L. (V.) guyanensis (A) and L. (V.) braziliensis (B) during 0–3 h of SbIII
incubation. The efﬂux rates of L. (V.) guyanensis (C) and L. (V.) braziliensis (D) were determined during 0–2 h. Data shown are the means of three independent experiments in
triplicate of antimony concentration ± SEM. Statistically different values are highlighted as follows: ⁄p < 0.01, ⁄⁄p < 0.02 and ⁄⁄⁄p < 0.05.
Fig. 7. Expression level of AQP1 protein in Leishmania spp. susceptible and resistant lines. Analysis of Western blot with the rabbit polyclonal antibody against the AQP1
protein. The intensity of bands was quantiﬁed using ImageJ (http://rsbweb.nih.gov/ij/). Bands were normalized using a-tubulin and the intensity ratio is shown relative to the
WTS band (SbR/WTS).
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clude the entry, metabolism, efﬂux and/or sequestration, as well
as cell death through the drug action (Jeddi et al., 2011). MRPA is
one of the most studied ABC transporters in Leishmania and its role
in the resistance has been well established in vitro (Ouellette et al.,
1990). However, the majority of these studies were performed
using Old World drug-resistant Leishmania lines.
Our PFGE results showed that the MRPA gene is located in an
800 kb band corresponding to chromosome 23 (795 kb) of Leish-
mania, corroborating literature data (Leprohon et al., 2009; Monte
Neto et al., 2011). Interestingly, the MRPA gene probe also recog-
nized two other bands of different sizes, 200 and 1500 kb, only in
the antimony-resistant L. braziliensis line. These supplementary
bands indicate thatMRPA is rearranged or present as an extrachro-
mosomal ampliﬁcation in LbSbR (Fig. 1B). Additionally, the smear
observed exclusively in this resistant line, provide an evidence of
circular DNA ampliﬁcation as indicated by this particular migrationin PFGE possibly corresponding to various topoisomers of the cir-
cles (White et al., 1988). According to Beverley (1988), large super-
coiled circular DNAs appear to exhibit unusual electrophoretic
mobility in PFGE, when compared to the large linear chromosomes.
Then, an explanation for the presence of approximately 1500 kb
chromosomal band in the antimony-resistant L. braziliensis line
may be related to the integration of this band into large linear
chromosomal DNA or the formation of large concatenated net-
works of circular DNA. Moreover, Grondin et al. (1998) demon-
strated the formation of extrachromosomal circular DNA
ampliﬁcation derived from precursors linear amplicons in metho-
trexate-resistant L. tarentolae. This possibility could explain the
presence of additional bands concomitant with the smear detected
by MRPA gene probe in the same LbSbR line. It is also important to
note that theMRPA gene probe recognized a band of approximately
700 kb only in the antimony-resistant L. infantum line. It is de-
scribed in the literature that the variability in the chromosomal
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of different sizes, variation in the size of the telomeric regions,
small deletions or insertions (Henriksson et al., 1993). However,
the formation of a MRPA-containing linear extrachromosomal
DNA ampliﬁcation in LiSbR is not discarded. Further studies could
conﬁrm the presence of supernumerary chromosomes in these
New World Leishmania parasites as suggested by MRPA hybridiza-
tion as well as by the presence of a new band in LgSbR compared to
LgWTS (Fig. 1A, white arrow). Aneuploidy was a phenomenon pre-
viously described in drug-resistant Old World Leishmania parasites
(Ubeda et al., 2008; Leprohon et al., 2009; Downing et al., 2011)
and it supports the evidence of the genome structural plasticity
requirement to adapt and survive in the presence of the drug.
Literature data also show the presence of extrachromosomal
MRPA ampliﬁcation in other Leishmania species. Anacleto et al.
(2003) reported the presence of extrachromosomal amplicon of
30 kb containing the PgpA gene in L. guyanensis with in vitro-in-
duced resistance to Glucantime. Mukherjee et al. (2007) observed
that theMRPA genewas ampliﬁed in clinical isolates of sodium anti-
mony gluconate (SAG)-resistant L. donovani lines studied. Recently,
Monte Neto et al. (2011) observed that theMRPA gene is present in
extrachromosomal linear amplicons in two independentmutants of
antimony-resistant L. amazonensis. Sampaio and Traub-Cseko
(2003) reported the presence of ampliﬁcation of the biopterin trans-
porter in a linear and stable chromosome of 245 kb in L. braziliensis
(M2903 strain). However, the results obtained by Dias et al. (2007)
suggest that in L. braziliensis the generation of amplicons is not a
common phenomenon when this specie is subjected to drug pres-
sure. Nevertheless, our results in antimony-resistant L. braziliensis
line indicate that extrachromosomal ampliﬁcation of theMRPA gene
may occur, corroborating the data of Sampaio and Traub-Cseko
(2003). A possible explanation for the lack of ampliﬁcation in the
samples of L. braziliensis analyzed by Dias et al. (2007) may be due
to differences in the antimony-resistance level and the protocol
used to obtain the resistant parasites when compared to our study.
Our data showed that MRPA transcripts are twice as high in the
antimony-resistant L. guyanensis, L. amazonensis and L. braziliensis
lines, compared to their wild-type pairs. This data correlates with
the ampliﬁcation of this gene in antimony-resistant lines, as shown
in PFGE and Southern blot assays. However, the MRPA gene ampli-
ﬁcation of SbIII-resistant L. braziliensis line (10-fold higher) does
not reﬂect in the level of mRNA that was only two-fold higher than
its susceptible counterpart. This could also be due to post-tran-
scriptional control that decreases the RNA levels of this gene
(Teixeira, 1998). It was shown by targeted DNA microarray that
the MRPA transporter is overexpressed in axenic amastigotes of
antimony-resistant L. infantum (El Fadili et al., 2005). Recently,
Monte Neto et al. (2011) reported an overexpression of this gene
in antimony-resistant L. amazonensis, using whole-genome DNA
microarrays. Transcriptome data of L. donovani from antimony-
resistant clinical isolates demonstrated that the MRPA gene is not
increased in these resistant parasites samples (Decuypere et al.,
2005). These differences could be explained by the diversity in
resistance indexes as well as in the resistance phenotype stability
from different species and genetic background (Decuypere et al.,
2012).
A multidrug resistance phenotype associated with the overex-
pression of Pgp was found in tumoral cell lines and in different
pathogenic protozoa (Ullman, 1995). In this study, we investigated
whether Pgp, which is a product of the MDR1 gene, was also over-
expressed in our antimony-resistant Leishmania lines. Our results
showed that the anti-Pgp antibody C219 detected a 170 kDa poly-
peptide corresponding to the expected size for Pgp. Interestingly,
this protein is more expressed in the antimony-resistant L. guyan-
ensis and L. amazonensis lines. However, no difference in Pgp
expression between antimony-susceptible and -resistant lines ofL. infantum was detected, suggesting that Pgp may be not involved
in drug resistance in this Leishmania species.
In this study, we used the technique of graphite furnace atomic
absorption spectrometry to measure the amount of antimony
accumulated in the Leishmania species. Our data show that the
incorporation of antimony was reduced in the antimony-resistant
L. guyanensis, L. amazonensis and L. braziliensis lines (Fig. 5). Litera-
ture data demonstrated that antimony-resistant L. infantum and L.
panamensis lines incorporated less antimony, when compared to
their susceptible pairs (Brochu et al., 2003). Maharjan et al.
(2008) also showed that the SAG-resistant clinical isolates of L.
donovani accumulated about three- to seven-fold less antimony
compared to clinical isolates susceptible to this drug. All these lit-
erature data corroborate our ﬁndings, showing that the resistant
parasites accumulate less antimony compared with the respective
susceptible pairs.
It has been reported that AQP1 is an important carrier for which
cells can accumulate SbIII in Leishmania (Borgnia et al., 1999; Gour-
bal et al., 2004; Marquis et al., 2005). Our results revealed reduced
expression of the AQP1 protein in the SbIII-resistant lines of L.
guyanensis and L. amazonensis. Thus, this result may explain, at
least in part, the reduced uptake of antimony in these resistant
lines of the parasite. In fact, previous studies have shown that
the reduced accumulation of SbIII in resistant mutants to this com-
pound could be due to decreased activity of AQP1 and that loss of
an allele of this gene can cause an increase in the resistance (Gour-
bal et al., 2004; Marquis et al., 2005; Mukherjee et al., 2013). It is
also possible that another transporter may be involved in the low
accumulation of antimony in resistant Leishmania lines. On the
other hand, no signiﬁcant difference of antimony incorporation
was observed between the antimony-susceptible and -resistant
lines of L. infantum. This can be explained due to the low resistance
index of this antimony-resistant line. These data of antimony accu-
mulation suggest the presence of different antimony-resistance
mechanisms among these Leishmania species analyzed.
We investigated the SbIII efﬂux rates in lines of L. guyanensis
and L. braziliensis. The results revealed that the efﬂux rates are
higher in the antimony-resistant lines of these parasites, contribut-
ing to the lower accumulation of SbIII in these Leishmania species
studied. Although, the SbIII-resistant L. braziliensis line present
low antimony concentration, the level of expression of AQP1 was
similar between both SbIII-susceptible and -resistant lines, sug-
gesting that the AQP1 is not involved in the antimony-resistance
phenotype. However, the SbIII-resistant L. braziliensis line showed
an increased rate of antimony efﬂux, which could explain in part
the lower SbIII accumulation in this line.
Interestingly, susceptibility test to BSO, an inhibitor of c-glut-
amylcysteine synthetase (GCS), showed that this inhibitor reversed
the SbIII-resistance phenotype of L. braziliensis. The LbSbR line was
more susceptible to BSO than its susceptible counterpart LbWTS.
More importantly, with BSO pre-treatment, the resistant parasites
LbSbR became 32-fold more susceptible to SbIII than those without
treatment. Additionally, we analyzed the effect of the BSO in the
uptake of antimony in the lines of L. braziliensis pre-treated with
this inhibitor. Our results showed that the SbIII-resistant line accu-
mulated more antimony than its wild-type counterpart, suggesting
this inhibitor interferes in the polyamine metabolism, changing the
intracellular concentration of thiols and antimony. Indeed, in vitro
studies have shown that BSO, a speciﬁc inhibitor of GCS, an enzyme
involved in glutathione and trypanothione biosynthesis, can re-
verse resistance to trivalent antimony in the parasite L. tarentolae
(Grondin et al., 1997).
In conclusion, our data show that the antimony resistancemech-
anisms are different in the NewWorld Leishmania species analyzed
in this study. Functional analysis studieswill be performed to inves-
tigate the involvement of theMRPA gene in our Leishmania samples.
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